So long as AMRN stays with the "go it alone" strategy they will be doing additional stock offerings. AMRN management has stated they plan to diversify their product offerings by acquiring other drug candidates. The only way this will end is if Vascepa is wildly successful or they accept a takeover offer by BP. I am confidant enough about Vascepa's prospects that none of this is of concern.